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IMMUNOHISTOCHEMICAL 
DETECTION OF P53 PROTEIN 
IS NOT ASSOCIATED WITH A 
POOR PROGNOSIS IN NON- 
SMALL-CELL LUNG CANCER 
Immunohistochemical detection of the p53 gene product by monoclonal antibodies 
has been shown to be associated with a poor clinical outcome in carcinomas of the 
breast and stomach. Because the prognostic relevance of p53 immunostaining in
lung cancer is still under debate, we studied the expression pattern and clinical 
significance of such staining in 73 patients with operable non-small-cell lung cancer. 
p53 expression was detected on frozen sections with the use of monoclonal ntibody 
p1801, which recognizes both the wild-type and mutant gene product (alkaline 
phosphatase-anti-alkaline phosphatase method). A tumor was considered p53 
positive if more than 1% of the tumor cells were stained. The p53 expression pattern 
was compared with clinicopathologic parameters, and analysis of follow-up, based 
on the data of 65 patients, was done by a log rank test (median observation time.j 780 
days). Nuclear p53 staining was detected in 33 of 73 non-small-cell lung cancers 
(45.2%). Comparison with clinicopathologic parameters demonstrated that the p53 
protein was detected more frequently in younger patients (younger than 50 years, 
p = 0.014), whereas no correlation was found with sex, tumor differentiation, tumor 
histologic type, or TNM stage. Surprisingly, follow-up analysis revealed that p53 
staining was associated with an increased rate of disease-free survival, especially in 
patients with early stage tumor disease (p = 0.004) and in male patients (p = 0.023). 
Counter to previous tudies in other solid tumors, immunocytochemical detection of 
p53 expression does not predict a poor clinical outcome in non-small-cell ung 
cancer. In early-stage lung cancer it might be associated with an  improved 
disease-free survival, which suggests hat the majority of the detected protein 
inherits the wild-type tumor suppressor function. (J THORAC CARDIOVASC SURG 
1995;109:1205-11) 
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T he prognosis of patients with non-small-cell lung cancer (NSCLC) is still poor. The disease in most 
patients is inoperable at the time of diagnosis and in 
patients with operable primary tumors metastatic 
relapse is a frequent event. In fact, about 40% to 
50% of the patients thought o have limited tumor 
disease (tumor stage I or II) will have a relapse 
within 3 years after operation, which indicates that 
these patients cannot be cured by operation alone. 1
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To identify these patients at risk, additional prog- 
nostic parameters need to be established. 
Mutations of the p53 gene play an important role 
in the carcinogenesis and progression of solid hu- 
man tumors. The expression of nuclear p53 is reg-- 
ulated during the cell cycle and it has been sug- 
gested that one of its main functions is to block the; 
transition from G0/Ga to the S phase of the cell 
cycle. 2 Recently, it has been demonstrated that by 
using the polymerase chain reaction-single strand 
conformation polymorphism (PCR-SSCP) assay, 
point mutations of the p53 gene occur in approxi- 
mately 45% of reseeted NSCLCs, and patients in 
which this occurs indeed have a poorer prognosis. 3 
Surprisingly, this prognostic influence was only sig- 
nificant in patients with advanced-stage disease, 
whereas the r lapse rate in patients at stages I and II 
were unaffected. 
An indirect but simpler method to detect p53 
mutations is based on the observation that in com- 
parison with the wild-type gene product, the mutant 
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Table I. Frequency of p53 expression in NSCLC 
No. of p53 + 
Parameter patients (%)* p53 p Valuer 
All patients 73 33 (45.2) 40 - -  
Age (yr) 
< 50 15 11 (73.3) 4 
-> 50 58 22 (37.9) 36 0.014 
Sex 
Female 16 8 (50.0) 8 
Male 57 25 (37.3) 32 0.662 
Grade of differentiation:) 
G1-2 34 15 (44.1) 19 
G3 37 18 (48.6) 19 0.702 
Tumor histologic type 
Adenocarcinoma 35 14 (40.0) 21 
Squamous cell 30 15 (50.0) 15 
carcinoma 
Adenosquamous 2 1 (50) 1 
carcinoma 
Large-cell carcinoma 6 3 (50) 3 0.864 
Tumor stage§ 
Stage I-II 38 20 (52.6) 18 
Stage IIIa-IV 34 12 (35.3) 22 0.139 
*Frequency ofp53 expression was determined byimmunohistochemistry 
using mAb p1801. A tumor was considered to be positive if more than 1% 
of tumor cells were stained. 
tPearson's X atest. 
Sin tumors with mixed histologic types grade of differentiation was not 
determined (n = 2). 
§In one patient tumor staging was not available. 
p53 gene product is more stable and has a prolonged 
half-life. 4 This accumulation of  mutant p53 protein 
allows its immunohistochemical detection on frozen 
or paratfin-embedded sections. In contrast to the 
PCR-SSCP assay, this technique can easily be done 
and established in clinical pathologic examinations. 
Hence detection of p53 mutations by immunohisto- 
chemistry might be a practicable tool leading to an 
improved staging of the disease in individual patients. 
We, therefore, performed a prospective study in 
73 patients with operable NSCLC using immunohis- 
tochemistry with the monoclonal antibody (mAb) 
p1801, which recognizes both the wild-type and 
mutant gene product. Counter to our expectations, 
we observed that immunohistochemical detection of 
p53 expression predicts an improved disease-free 
survival, which raises doubt on the suitability of p53 
immunostaining for indirect assessment of p53 gene 
mutations. 
Patients and methods 
Patients and follow-up. Tumor specimens from 73 pa- 
tients with NSCLC were examined. Before operation all 
patients underwent the conventional staging procedures 
and were found to have operable primary tumors (TNM 
stage less than or equal to T3 N2 M0). The median age at 
the time of operation was 59 years, range 38 to 77. In 
general obectomies or, if necessary, pneumonectomies 
were done, followed by a radical lymphadenectomy. Pa- 
tients whose tumors were classified pathologically as T3 
N2 M0 or higher after operation had adjuvant radiation 
therapy. 
Follow-up care was organized by the department of 
pulmonary medicine. Evaluation included physical exam- 
ination, chest roentgenography, and blood examinations 
every 3 months and bronchoscopy, computed tomographic 
scan of the thorax, abdominal ultrasonography, and a 
bone scan every 6 months after operation. Complete 
information was obtained from a representative group of 
65 patients with a median follow-up of 780 days (range 450 
to 1170). Six patients with deaths unrelated to cancer have 
been excluded from the analyses (n = 3 in the p53-positive 
group and n = 3 in the p53-negative group). Two patients 
were lost to follow-up. 
Tumor samples and immnnohistochemistry. Repre- 
sentative tumor samples were obtained from the fresh 
surgical specimen and immediately snap-frozen i  liquid 
nitrogen. The frozen tissue was stored at -80 ° C until use. 
Out of each frozen tumor sample 10 to 15 serial cryostat 
sections of 5 tzm thickness were cut and transferred onto 
glass slides. After air drying for 24 hours, slides were 
stored at -20 ° C. 
p53 protein was detected by mAb p1801 (immunoglob- 
ulin [Ig] G1, Dianova, Hamburg, Germany), which recog- 
nizes both the wild-type and mutant gene product. 
For immunohistochemistry he slides were fixed in 
acetone for !0 minutes and air dried for 45 minutes. Then 
the cryostat sections were stained according to the alka- 
line phosphatase-anti-alkaline phosphatase (APAAP) 
staining procedure described by Cordell and associates. 5 
After rehydration through incubation with Tris-buffered 
sq!ution (pH 7.6) for 15 minutes, AB serum (pooled 
serum from donors with blood group AB, diluted" 1:10 
with phosphate-buffered solution; Biotest, Dreieich, Ger- 
many) was applied for 20 minutes to block unspecific 
binding. Subsequently, specimens were incubated for 45 
minutes with the primary antibody diluted with Tris- 
buffered solution (1:50). After each incubation step, the 
slides were washed three times with Tris-buffered solu- 
tion. The bridging antibody (Dako Corp., Carpenteria, 
Calif.) was applied for 30 minutes, followed by incubation 
with the APAAP complex (Dako) for 30 minutes. Staining 
was visualized by the Neufuchsin method. Counterstain- 
ing was done with Mayer's hemalum solution. 
As a negative control for unspecific antibody binding, 
the primary antibody was replaced by an irrelevant mouse 
myeloma protein of identical isotype (MOPC 21, IgG1; 
Sigma, Deisenhofen, Germany). 
Evaluation of the specimens. The slides were evalu- 
ated, in a double-blind fashion, by two observers with light 
microscopy. A tumor was considered p53 positive if more 
than 1% of all visible tumor cells were stained. Localiza- 
tion of the epithelial tumor cells within the specimen was 
confirmed by the anti-epithelial antibody EP4 (IgG1, 
Dako6), which stains more than 96% of all bronchogenic 
carcinomas (data not shown). 
In approximately 85% of the cases both observers 
obtained the same results; the remaining slides were 
reevaluated and a consensus decision was made. 
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Fig. 1. Immunostaining of p53 protein (APAAP method) with mAb p1801 of squamous cell carcinoma f 
lung (tumor stage I) demonstrating intense nuclear staining of about 60%of tumor cells. Surrounding 
peritumoral tissue remains free of stain. 
Statistical analysis. For comparison of clinicopatho- 
logic parameters contingency tables were tested by Pear- 
son's X 2 test. For analysis of follow-up data, Kaplan-Meier 
curves were calculated and a log rank test was done with 
the SPSS software package (SPSS Inc., Chicago, ILL). 
Results 
Expression of p53 in NSCLC. By immunohisto- 
chemistry and the mAb p1801, p53 nuclear staining 
was detected in 33 (45.2%) of 73 patients with 
operable NSCLC (Table I, Fig. 1). The staining was 
limited to the nucleus in 29 cases, but some addi- 
tional, weak cytoplasmatic staining was observed in 
four tumors. With a semiquantitative score less than 
30% of the tumor cells were stained in 21.2% (7 of 
33) of the tumors, in 45.5% (15 of 33) between 30% 
and 60% of the tumor cells were positive, and 33.3% 
(11 of 33) of the neoplasms displayed more than 
60% positive cells. Normal lung tissue was always 
negative for p53 staining. 
Comparison with clinicopathologic parameters 
demonstrated that the p53 protein was detected 
more frequently in younger patients (younger than 
50 years; p = 0.014), whereas no correlation was 
found with sex, tumor grading, tumor histologic 
type, or TNM stage (Table I). 
Prognostic significance of p53 expression. After 
a median observation time of 780 days, follow-up 
analysis revealed that p53 expression tended to be 
associated with an increased rate of disease-free 
survival (p = 0.134, Fig. 2, A, Table II). This 
difference was significant in male patients (p = 
0.023) and in patients with early-stage tumor disease 
(stage I or II, p = 0.004, Fig. 2, B). p53 expression 
was not of prognostic significance in patients with 
advanced tumor disease (Fig. 2, C). Interestingly, 
four out of the eight female patients with p53- 
positive tumors had a relapse within the observation 
period, in contrast o none of the female patients 
with p53-negative tumors, which suggests that in 
women p53 expression might be associated with a 
poorer prognosis. 
Discussion 
Mutations of the p53 gene have been described in 
different ypes of cancer and they play an important 
role in tumorigenesis and progression of certain 
solid tumors. The wild-type protein has a half-life 
time of only 5 to 10 minutes, which an be prolonged 
up to 30-fold in transformed cells with mutant forms 
of p53 protein resulting in its accumulation i the 
nucleus. 4 Therefore, instead of demonstrating the 
gene mutation directly by deoxyribonucleic acid 
(DNA) sequencing or PCR-SSCP technology, im- 
munohistochemical methods were used in the 
present study to indirectly assess p53 mutations. 
Nevertheless it is noteworthy that p53 protein can 
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Fig. 2. Influence of p53 immunostaining on disease-free survival in patients with NSCLC. A, All patients. 
B, Patients with tumor stages I or II. C, Patients with tumor stages IIa through IV. Tumors were scored as 
positive if more than 1% of tumor cells were stained with mAb p1801 (p values by log rank test). 
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also be detected by immunohistochemistry despite 
the absence of a mutant p53 gene. 7
In total, detectable p53 protein was found in 
45.2% of the patients, which corresponds to findings 
in the respective work on NSCLC reported in the 
literature, including the incidence of mutations de- 
rived from DNA sequencing and PCR-SSCP analy- 
sis (Table III). Unspecific staining of cells was 
excluded by the use of an unrelated control antibody 
of the same immunoglobulin sotype as the anti-p53 
mAb p1801. The majority of specimens displayed a
nuclear staining of tumor cells. The biologic mean- 
ing of the cytoplasmatic staining observed in four 
samples is unclear. One explanation is that p53 
protein can be stabilized in the cytoplasm through 
conjugation with other components uch as heat 
shock proteins or mdm2 (murine double minute-2), 
a gene encoding for a nuclear phosphoprotein that 
may interact with both the mutant and wild-type p53 
protein. 
The definition of cutoff values in the analysis of 
immunohistochemical stainings is an obvious prob- 
lem. 8 Because the most invasive or metastatic clone 
of a primary tumor might account for only a small 
fraction of the entire tumor mass we decided to 
chose a low cutoff value. However, it should be 
noted that only seven of 33 tumors contained less 
than 30% p53-positive tumor cells. 
With the exception of a preferential expression of 
p53 protein in younger patients (Table I), our 
present data confirm the results of several previous 
studies that demonstrated no correlation between 
p53 expression and conventional risk factors. In the 
only two reports that describe an association be- 
tween p53 expression and an advanced tumor stage, 
these correlations were either relatively weak 9 or 
based on the combination of different detection 
methods. 7 Thus the prognostic significance of p53 
alterations in NSCLC is still a point of contention. 
In the present study, we demonstrate for the first 
time that p53 protein detected by immunohisto- 
chemistry is not associated with an unfavorable 
prognosis in patients with early-stage NSCLC. This 
is in contrast to the results reported by Quinlan and 
coworkers, 1° who used the same anti-p53 mAb but 
described a poorer prognosis in patients with posi- 
tive p53 staining. However, paraffin sections were 
used in this retrospective study, which might have 
hampered immunostaining. Furthermore the value 
of statistical analysis done in that study remains 
unclear, because of the lack of information on the 
length of the observation period and the use of 9( 2 
Table II. Prognostic significance of p53 expression 
in NSCLC 
No. of 
No. of tumor 
patients recurrences 
Parameter at risk (%) p Value* 
All patientst 
p53 + 30 14 (46.7) 
p53 35 20 (57.1) 0.134 
Age (yr) 
<50 
p53 + 11 4 (36.4) 
p53- 4 2 (50.0) 0.599 
->50 
p53 + 19 10 (54.5) 
p53- 31 18 (58.1) 0.230 
Sex 
Female 
p53 + 8 4 (50.0) 
p53- 6 0 0.057 
Male 
p53 + 22 10 (45.5) 
p53- 29 20 (69.0) 0.023 
Grade of differentiations 
G1-2 
p53 + 13 6 (46.2) 
p53 16 8 (50.0) 0.654 
G3 
p53 + 17 8 (47.1) 
p53 18 12 (66.7) 0.106 
Tumor histologic type§ 
Adenocarcinoma 
p53 + 12 5 (41.7) 
p53- 17 10 (58.8) 0.124 
Squamous 
p53 + 14 8 (57.1) 
p53- 14 8 (57.1) 0.442 
Tumor stageli 
Stage I-II 
p53 + 18 3 (16.7) 
p53 16 8 (50.0) 0.004 
Stage IIIa-IV 
p53 + 11 10 (90.0) 
p53 19 12 (63.2) 0.465 
*p Value by log-rank test. 
tFollow-up data were available from 65 patients. 
:~Tumors with mixed histologic types were not analyzed (n = 1). 
§Because of the small numbers tumors with mixed histologic types and 
large-cell carcinomas were not included. 
[[In one patient umor staging was not available. 
analysis of Kaplan-Meier curves. Although the 
follow-up period of our study was relatively short, 
most tumor recurrences in patients with NSCLC 
occur within the first 3 postoperative years. The 
presented ata might therefore be meaningful. By 
stratifying the patients for tumor stage the relative 
numbers in each subgroup become small, which 
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Table IlL p53 in NSCLC 
No. of 
Author patients Method mAb 
Percentage 
ofp53- 
posilive 
tumors 
Correlation to Correlation to 
clinicopathologic parameters prognosis 
Fontanini (1993) 9 
Marchetti (1993) 7 
Horio (1993) 11 
Quinlan (1992) 1° 
Iggo (1990) 16 
Hiyoshi (1992) 17 
Chiba (1990) TM 
Mitsudomi (1993) 3 
100 Immunocytochemistry (f ozen p240 35.9 
sections, ABC method) p1801 68.0 
53 Immunocytochemistry (f ozen p240 58.0 
sections, ABC method) p1801 
PCR-SSCP 47.0 
Immunocytochemistry + PCR- 75.0 
SSCP 
70 PCR-SSCP - -  49.0 
114 Immunocytochemistry (paraffin p1801 42.9 
sections, ABC method) 
40 Immunocytochemistry (f ozen p240, 55.3 
sections, APAAP method) JG8 
88 Immunocytochemistry (paraffin p1801 49.0 
sections, ABC method) 
51 cDNA sequencing - -  45.0 
120 PCR-SSCP - -  43.0 
Higher expression in N1-3 Not determined 
No correlation Not determined 
No correlation 
Higher expression i  N1-3 
and stage II-III 
No correlation 
No correlation 
Not determined 
Not determined 
Poorer prognosis 
Poorer prognosis 
Not determined Not determined 
No correlation Not determined 
More frequent in squamous Not determined 
carcinomas 
More frequent in squamous Poorer prognosis 
carcinomas 
ABC, Avidin-biotin-peroxidase complex technique. 
results in a certain insecurity with respect o the 
conclusions on the proposed beneficial impact of 
p53-positivity in patients with node-negative dis- 
ease. The apparent evidence for a beneficial impact 
of p53 staining on prognosis in patients with node- 
negative disease (Fig. 2) is therefore only suggestive 
and needs to be corroborated in more extensive 
clinical investigations. Thus far, evaluation of over- 
all survival has not revealed any significant changes 
between patients with p53-positive and p53-negative 
tumors (data not shown). However, it appears to be 
sufficient o present data on disease-flee survival, 
because in patients with NSCLC the detection of a 
tumor recurrence within the first 3 years after 
operation is closely associated with a cancer-related 
death in the following years. To support this as- 
sumption we analyzed the follow-up data from 220 
patients with NSCLC operated on in our clinic 
between March 1989 and December 1991. A total of 
114 of 220 patients had a tumor recurrence within 
the first 3 years after operation and 95 (83.8%) of 
these 114 patients died of their disease within the 
subsequent 3 years (data not shown). 
There are two reports in which the PCR-SSCP 
technique is used, and both describe a poorer prog- 
nosis for patients with NSCLC with p53 muta- 
tions. TM Although Mitsudomi and colleagues 3 
found a significant prediction only in advanced-stage 
tumors, Horio and coworkers 11 described a short- 
ened survival in all patients bearing p53 mutations 
independent from tumor stage. These findings are 
not in contrast to our results, because immunostain- 
ing for p53 with mAb p1801 might also include the 
detection of wild-type protein rather than the spe- 
cific staining of the mutant gene product. This view 
is supported by the recent observation that in more 
than 30% of NSCLCs p53 overexpression without 
p53 mutation occurred] Antibodies to specific on- 
formations of the mutant p53 protein are also 
available. However, the use of these antibodies in 
immunohistochemical analysis is greatly hampered 
by the fact that the specificity can be abolished on 
air-dried and fixed specimens, leading to unspecific 
staining (data not shown). 
A better prognosis for patients with p53-positive 
tumors has also been described for patients with 
squamous cell carcinoma of the tongue, 12 whereas in 
patients with carcinoma of the esophagus the prog- 
nosis was independent from p53 immunostainingJ 3 
Thus the prognostic significance of p53 immuno- 
staining might depend on the particular type of 
carcinoma nd might be influenced by the continu- 
ous exposure to specific arcinogens such as tobacco 
smoke. In this context it is noteworthy that overex- 
pression of wild-type p53 protein leads to a block in 
the G o phase of the cell cycle, which allows DNA 
repair to be executedJ 4'a5 Thus lung tumor cells 
with high amounts of wild-type p53 might be able to 
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protect themselves more effectively against exoge- 
nous DNA-damaging agents. This could explain the 
prognostic influence observed in our study and that 
in squamous cell carcinoma of the tongue. This inter- 
pretation of why positive immunostaining might be 
related to improved isease-free survival is, however, 
speculative. Although immunostaining in general de- 
tects a greater frequency of p53 abnormalities than 
SSCP analysis for mutation, it is currently thought that 
the additional abnormalities probably represent accu- 
mulation of wild-type p53 protein by virtue of its 
having been complexed (for example with mdm2). 
This does not mean that accumulation of the wild-type 
p53 has a tumor-suppressor effect. In fact, just the 
opposite may be true. 
In conclusion, the present findings provide sug- 
gestive evidence that immunocytochemical detec- 
tion of p53 protein in patients with NSCLC predicts 
a better prognosis in tumor stages I and II. Although 
this conclusion needs to be confirmed in a larger 
clinical study, one might speculate that the approach 
presented here may be used to determine the risk of 
relapse in patients with early-stage NSCLC with 
potential consequences for adjuvant therapy. 
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